Background Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to reduce risk of stroke but whether one treatment strategy is more eff ective than the other is unknown. We compared their effi cacy in the Cervical Artery Dissection in Stroke Study (CADISS), with the additional aim of establishing the true risk of recurrent stroke.
Introduction
Cervical artery dissection accounts for only 1-2% of all ischaemic strokes, but in young and middle-aged people it accounts for 10-25% of strokes.
1 Some studies suggest a signifi cantly increased risk of stroke in patients presenting with dissection either with local symptoms, such as headache and Horner's syndrome, or with stroke or transient ischaemic attack, with estimates of the risk of secondary stroke after presentation of 15-20%, 2-4 although other studies have reported a much lower proportion. 5 These studies suggested that most strokes occurred soon after initial onset of symptoms. Embolism from thrombus forming at the dissection site is thought to play the major part in stroke pathogenesis. 6 This suggestion is supported by transcranial Doppler studies 7, 8 showing cerebral microemboli soon after dissection, and by the distribution of infarcts after dissection, which suggests an embolic pattern. 9 The risk of early recurrence of stroke has led many clinicians to advocate the use of anticoagulation from presentation until 3 or 6 months after dissection. However others believe that antiplatelet drugs might be suffi cient. 10 Anticoagulants might prevent embolism from a fresh thrombus but they are also more hazardous than antiplatelet drugs and can result in extension of the intramural haemorrhage, which occurs in a third of patients according to MRI. 11 No data exist from randomised controlled trials assessing the relative effi cacy of the two treatments.
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This online publication has been corrected. The corrected version fi rst appeared at thelancet.com/ neurology on May 11, 2014 The Cervical Artery Dissection In Stroke Study (CADISS) was established to compare the eff ectiveness of antiplatelet drugs with anticoagulant drugs for the prevention of recurrent stroke in patients with carotid and vertebral dissection. It was established as a phase 2 feasibility trial with a planned sample size of 250 to enable accurate estimation of the rate of recurrent stroke and thereby samples sizes for a defi nitive phase 3 trial to be calculated.
Methods

Study design and participants
We did this randomised open-label parallel randomised trial at hospitals with specialised stroke or neurology services in the UK (n=39) and Australia (n=7) . The full study protocol has been previously published. 12 We enrolled patients from inpatient or outpatient services who had extracranial carotid or vertebral artery dissection with onset of symptom within the past 7 days, and imaging evidence of defi nite or probable dissection. Patients who had had stroke or transient ischaemic attack within the past 7 days were eligible. Imaging evidence of dissection had to be by MRI or magnetic resonance angio graphy, CT angiography, or intra-arterial angiography: although patients could be randomised on the basis of ultrasound alone, subsequent confi rmation with MRI, magnetic resonance angiography, or CT angiography was required.
Exclusion criteria were: intracranial cerebral artery dissection; contraindications to either antiplatelet or anticoagulation drugs, including active peptic ulceration or bleeding peptic ulcer within 1 year; use of antiplatelet or anticoagulants drugs for other reasons (eg, prosthetic heart valves) for which the treatment cannot be replaced with either antiplatelet or anticoagulant drugs; and pregnancy.
The study was approved by ethics committees of all participating centres in Australia and the UK. All patients gave written informed consent before enrolment.
Randomisation and masking
Patients were randomly assigned (1:1) to either antiplatelet treatment or anticoagulation treatment by an automated telephone randomisation service provided by the University of Aberdeen (Aberdeen, UK). Both patients and clinicians were aware of treatment allocation, but an adjudication committee that assessed all primary and secondary endpoints were masked to treatment allocation.
Procedures
The choice of antiplatelet drug or anticoagulant drug was at the discretion of the local physician. Antiplatelet treatments included aspirin, dipyridamole, or clopidogrel alone or in combination. For patients assigned to anticoagulation, treatment with heparin (either un fractionated heparin or a therapeutic dose of low-molecularweight heparin) was followed by warfarin, aiming for an international normalised ratio of 2-3. Novel oral anticoagulants were not used. Low-dose heparin prophylaxis for prevention of deep-vein thrombosis was not a contraindication, but its use was recorded. Such prophylaxis could be continued after randomisation in the antiplatelet group at the discretion of the local clinician.
Patients were followed up at 3 months after randomisation, when data for outcome and occurrence of recurrent stroke and transient ischaemic attack were recorded. Repeat imaging with magnetic resonance angiography or CT angiography to assess vessel recanalisation was done whenever possible at the 3-month follow up visit.
Outcomes
The primary endpoint was ipsilateral stroke or death (any cause) within 3 months of randomisation in the intention-to-treat population. For vertebral dissection, an ipsilateral event was defi ned as a recurrent event in the vertebrobasilar territory. Secondary endpoints were: ipsilateral transient ischaemic attack (including amaurosis fugax), stroke, or death (any cause); any stroke or death (any cause); any stroke, death, or major bleeding; any stroke; any transient ischaemic attack (including amaurosis fugax) or stroke; death; residual stenosis (>50%); and major bleeding.
Major bleeding was defi ned according to the International Society on Thrombosis and Haemostasis defi nition: 13 
Statistical analysis
We planned to enrol 250 participants on the basis of observational studies. [2] [3] [4] We did no interim analyses. All enrolled patients were included in the intention-totreat population. We also did a per-protocol analysis, which excluded any patient who did not meet inclusion criteria for any reason, including failure to confi rm diagnosis of dissection on central review of imaging. We calculated exact CIs with the binomial (Clopper-Pearson) exact method. We compared the treatment eff ect in each group by exact logistic regression (Stata, version 13). We did the other analyses with SPSS (version 20).
We did power calculations to estimate the sample size needed for a defi nitive phase 3 trial with an online power calculator. These calculations were based on the combined endpoint of stroke, death, and major bleeding, with a power of 0·8 and a p value of 0·05.
This trial is registered with EudraCT (2006-002827-18 ) and ISRN (CTN44555237) and was adopted by the English National Institute for Health Research Clinical Research Network (2181).
Role of the funding source
The funder had no role in study design, data collection, analysis, or interpretation, writing of the report, or the decision to submit for publication. All authors had full access to all the data in the study. The fi nal decision to submit the report for publication was made by HSM.
Results
We recruited 250 patients between Feb 24, 2006, and June 17, 2013. 118 had carotid dissection and 132 had vertebral arterial dissection. Mean time to randomisation was 3·65 days (SD 1·91). 174 (70%) of participants were male. Mean age was 49 years (SD 12, . 126 participants were randomly assigned to antiplatelet treatment and 124 to anticoagulation treatment (fi gure). The major presenting symptoms were cerebral ischaemic in 224 patients (195 ischaemic stroke, 29 transient ischaemic attack) and local symptoms in 26 patients (22 headache, 22 neck pain, four Horner's syndrome). Table 1 shows baseline characteristics. All patients were followed up for 3 months.
In the antiplatelet group, 28 (22%) of 126 patients received aspirin alone, 42 (33%) received clopidogrel alone, one (1%) received dipyridamole alone, 35 (28%) received aspirin and clopidogrel, and 20 (16%) received aspirin and dipyridamole. In the anticoagulant group, 112 (90%) of 124 patients received heparin and warfarin and 12 (10%) received warfarin alone.
Original brain imaging and angiographic imaging was reviewed for all patients throughout the study and before the database was locked. Dissection was confi rmed for 198 patients (102 in the antiplatelet group, 96 in the anticoagulant group). For one patient in the antiplatelet group, although recruited within 7 days, randomisation was not done until day 9 because of a technical error. Therefore the per-protocol analysis included 197 patients (101 in the antiplatelet group, 96 in the anticoagulant group). 49·3 (12) 49·2 (12) 48·5 (12) 48·1 (11 Overall, stroke recurred in four (2%) of 250 patients in the intention-to-treat population: three in the antiplatelet group versus one in the anticoagulant group, all ipsilateral (appendix p 2). All recurrent strokes occurred in patients in whom the presenting symptom was stroke (four [2%] of 194 patients; three carotid, one vertebrobasilar).No deaths occurred, therefore the primary endpoint of ipsilateral stroke or death occurred in three (2%) of 126 patients in the antiplatelet group versus one (1%) of 124 in the anticoagulant group (odds ratio 0·335, 95% CI 0·006-4·233; p=0·63; table 2). In the per-protocol population, stroke recurred in four (2%) of 196 patients overall, and in four (3%) of 151 who presented with stroke (appendix).
For the intention-to-treat population, ipsilateral transient ischaemic attack occurred in one (1%) of 126 patients in the antiplatelet group versus four (3%) of 124 patients in the anticoagulant group (one [1%] of 101 vs three [3%] of 96 in the per-protocol population). Other transient ischaemic attack occurred in only one patient in the antiplatelet group, in both the intention-to-treat and per-protocol populations (appendix).
None of the secondary endpoints diff ered signifi cantly between treatment groups. Results in the intention-totreat and per-protocol populations were much the same (table 2) . Table 3 shows adverse events. One major bleed occurred in the anticoagulant group (none in the antiplatelet group), in a patient with vertebral dissection with extension intracranially who developed a subarachnoid haemorrhage. This patient presented with headache with no focal neurological symptoms and CT brain imaging showed intraventricular blood. Two minor bleeds occurred in the anticoagulant group (one haematuria and one haemoptysis), and none in the antiplatelet group.
To establish whether recurrent events might have occurred before recruitment and randomisation, we did a post-hoc analysis of patients presenting with stroke in whom previous transient ischaemic attack or minor stroke had occurred. In the intention-to-treat population, nine such patients were present in the anticoagulant group versus ten in the antiplatelet group (seven vs seven in the per-protocol population). The mean time between previous symptoms and subsequent stroke was 3·4 days (SD 5·5, range 0·04-21; median 1 day, IQR 0·25-4·0) in the intention-to-treat population, and 3·9 days (SD 6·3, range 0·13-21; median 1 day, IQR 0·3-5·0) in the perprotocol population.
Intention-to-treat population
Per-protocol population Four patients (two in each treatment group) had two adverse events; no patient had more than two adverse events. To assess the feasibility of a phase 3 trial, we did power calculations with the per-protocol data, and the composite outcome of stroke, death, or major bleeding (2·08%, 95% CI 0·25-7·32 in the anticoagulant group and 2·97%, 0·62-8·44 in the antiplatelet group). We calculated that a study with a power of 0·8 and signifi cance level of 0·05 would require a sample size of 4876 in each group.
Discussion
The results of our study, to our knowledge the fi rst randomised trial of antiplatelet treatment compared with anticoagulant treatment for extracranial carotid and vertebral artery dissection (panel), show that recurrent stroke at 3 months is rare, with no signifi cant diff erence between the two treatments. Although more strokes occurred in the antiplatelet group than in the anticoagulant group, this diff erence was counterbalanced by one major subarachnoid haemorrhage in the anticoagulant group.
The risk of recurrent events was lower than that reported in some observational studies. One of the fi rst studies, 2 which included 80 patients with carotid dissection (29 retrospectively and 51 prospectively recruited) reported recurrences in 17 (41%) of 41 patients presenting with transient ischaemic attack. In a prospective multicentre Canadian study, 3 in which follow-up data were available for 105 individuals, nine patients had stroke after presentation with either carotid or vertebral dissection, although fi ve recurrences were before study enrolment; the time between enrolment and onset of symptoms was not documented. By contrast, a retrospective analysis 15 of data from 298 patients with carotid dissection, all treated with either antiplatelet or anticoagulant drugs, reported fewer recurrences: 0·3% had ischaemic stroke, 3·4% had transient ischaemic attack, and 1·0% had retinal ischaemia. New ischaemic events were signifi cantly more common in patients with ischaemic events at onset (6·2%) than in patients with local symptoms or asymptomatic patients (1·1%). The results from the nonrandomised part of CADISS 6 reported a similarly low proportion: two (2%) recurrent strokes occurred during 3-month follow-up of 87 individuals with both carotid and vertebral artery dissection; however, mean time from symptom onset was 10·8 days (SD 7·0, range 1-31). In a trial setting, patients might have been recruited after they had already had their recurrent stroke; however, few patients in our study had such symptoms, suggesting this eff ect was not the reason for the diff erence in recurrence of stroke in CADISS compared with previous observational studies.
Because recurrences were rare, any defi nitive study examining this question is likely to need a very large sample size. Power calculations based on the per-protocol data and using the endpoint of stroke, death, or major bleeding gave a required total sample size of almost 10 000 participants, which will be diffi cult to recruit.
However, because the outcomes were rare, the 95% CIs for the endpoints were large and therefore the number of participants needed according to our calculation should be considered a rough estimate.
Diagnosis of dissection could not be centrally confi rmed on imaging review in about a fi fth of participants, despite evidence of dissection on angio graphic imaging or crosssectional imaging through the vessel wall. The failure to confi rm diagnosis was mainly caused by two factors. First, imaging was of poor quality for some participants and it was impossible to be sure of the diagnosis. Second, central review of imaging suggested an alternative diagnosis in some patients for whom imaging was of adequate quality. The most common alternative diagnoses were atherosclerosis, an atretic rather than dissected vertebral artery, a narrowed artery without any defi nite evidence of dissection and, in one case, adherent thrombus without clear evidence of dissection.
Several radiographic features suggest dissection, including appearance of a fl ap, tapering stenosis or pseudoaneurysm on angiography, and imaging of the arterial wall showing intramural blood. The diffi culties associated with diagnosis of dissection have been welldocumented. 16 For imaging of the vessel, diffi culties include limited spatial resolution, the tortuous course of arteries, variability in normal vessel calibre, presence of a thick bone covering, and adjacent veins. Imaging the vertebral arteries is more diffi cult than imaging the carotid arteries because of their smaller size, the fact that one is often atretic, and because fl ow-related enhancement of the vertebral plexus surrounding the artery can mimic intramural blood. 16 This greater diffi culty in diagnosis of vertebral dissection was shown by the lower proportion of confi rmed diagnoses for vertebral artery dissection (100 of 132) versus carotid dissection (98 of 118). However, the low proportion of confi rmed diagnoses and variations between recruitment sites suggest that training and quality control need to be improved. We did not use prespecifi ed imaging criteria; doing so might have improved the accuracy of diagnosis.
CADISS was designed as a pragmatic trial and therefore the choice of antiplatelet drugs was at the discretion of the clinician. Prescription of dual antiplatelet treatment for all patients might have improved effi cacy. Another limitation is that many patients did not have imaging confi rmation after central review; however, this shortcoming provides important information about routine clinical practice in the real world and a strength of the study was central review of imaging for all patients. Disease heterogeneity-eg, carotid versus vertebral dissection, or recent stroke versus local symptoms onlymight have caused diff erent groups to respond diff erently to treatments. Endpoints were too rare to assess such subgroups, but all recurrent strokes occurred in patients who had presented with stroke, consistent with previous data from obser vational studies, 15 suggesting this group are at the highest risk of recurrent event.
Generalisability is important in any clinical trial. To estimate the proportion of patients presenting with dissection who were recruited to the study, during the early part of CADISS, patients who were not randomly assigned (either because they did not meet the inclusion criteria or because the clinician or patient did agree to randomisation) could be entered into a non-randomised arm. 6 During this period, while 77 participants were recruited to the randomised arm, 88 patients screened for inclusion were not randomly assigned and instead entered the observational arm. Reasons for exclusion from the randomised arm were: presentation after 7 days (n=53), contraindication to antiplatelet or anticoagulant drugs (n=12), already taking antiplatelet or anticoagulation drugs for other reasons (n=5), patient or physician unwilling to randomise (n=18). 6 These fi ndings show that some patients (35 [21%] of 165) presenting within the 7-day window for inclusion in the randomised study were excluded.
In the observational arm of CADISS, stroke occurred in one (2%) of 59 patients treated with antiplatelet drugs, and in one (4%) of 28 patients treated with anticoagulant drugs. Some patients presenting with dissection, and perhaps particularly with very early, severe, recurrent stroke, might not have been included in either the observational or the randomised part of the study because they could not provide consent. Inclusion of patients within 24 h of onset of symptoms might have helped us to capture early recurrent strokes. However, some patients with dissection, particularly those with local symptoms, did not present on the day of onset. Furthermore, in the UK, a diagnosis of dissection might not be made until a couple of days after presentation because diagnostic angiographic or cross-sectional MRI is not always done at presentation. We therefore decided that a 7-day window would provide generalisable results, and also ensure that recruitment was feasible.
